Prestige Consumer Healthcare (FRA:PBV) Cyclically Adjusted Revenue per Share: €21.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PBV Prestige Consumer Healthcare Inc FRA:PBV
72 GF Score
Price €43.80
GF Value €59.76
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prestige Consumer Healthcare Cyclically Adjusted Revenue per Share?

Prestige Consumer Healthcare FRA:PBV +2.82% 72 Cyclically Adjusted Revenue per Share is €21.09 as of Jun. 2026. GuruFocus rates FRA:PBV with a GF Score™ of 72/100 and a GF Value™ of €59.76 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Prestige Consumer Healthcare's adjusted revenue per share for the three months ended in Jun. 2026 was €4.845. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €21.09 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Prestige Consumer Healthcare's average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Prestige Consumer Healthcare was 12.00% per year. The lowest was 5.20% per year. And the median was 10.40% per year.

As of today (2026-08-20), Prestige Consumer Healthcare's current stock price is €43.80. Prestige Consumer Healthcare's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €21.09. Prestige Consumer Healthcare's Cyclically Adjusted PS Ratio of today is 2.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Prestige Consumer Healthcare was 5.48. The lowest was 1.94. And the median was 2.91.


Prestige Consumer Healthcare  (FRA:PBV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Prestige Consumer Healthcare's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=43.80/21.09
=2.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Prestige Consumer Healthcare was 5.48. The lowest was 1.94. And the median was 2.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Prestige Consumer Healthcare Cyclically Adjusted Revenue per Share Related Terms


Prestige Consumer Healthcare Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Prestige Consumer Healthcare's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prestige Consumer Healthcare Cyclically Adjusted Revenue per Share Chart

Prestige Consumer Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.33 18.89 20.54 20.94 20.58

Prestige Consumer Healthcare Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.81 19.69 20.51 20.58 21.09

FRA:PBV vs BCRX, AMLX, SUPN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Cyclically Adjusted PS Ratio falls into.


FRA:PBV
72GF Score
Prestige Consumer Healthcare Inc FRA:PBV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prestige Consumer Healthcare Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Prestige Consumer Healthcare's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.845/333.9520*333.9520
=4.845

Current CPI (Jun. 2026) = 333.9520.

Prestige Consumer Healthcare Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 3.592 241.428 4.969
201612 3.851 241.432 5.327
201703 4.212 243.801 5.769
201706 4.268 244.955 5.819
201709 4.043 246.819 5.470
201712 4.271 246.524 5.786
201803 3.879 249.554 5.191
201806 4.107 251.989 5.443
201809 3.933 252.439 5.203
201812 4.065 251.233 5.403
201903 4.109 254.202 5.398
201906 3.948 256.143 5.147
201909 4.254 256.759 5.533
201912 4.277 256.974 5.558
202003 4.469 258.115 5.782
202006 4.009 257.797 5.193
202009 3.979 260.280 5.105
202012 3.882 260.474 4.977
202103 3.954 264.877 4.985
202106 4.409 271.696 5.419
202109 4.623 274.310 5.628
202112 4.769 278.802 5.712
202203 4.755 287.504 5.523
202206 5.167 296.311 5.823
202209 5.813 296.808 6.540
202212 5.183 296.797 5.832
202303 5.362 301.836 5.933
202306 5.136 305.109 5.622
202309 5.357 307.789 5.812
202312 5.173 306.746 5.632
202403 5.065 312.332 5.416
202406 4.937 314.175 5.248
202409 5.114 315.301 5.417
202412 5.546 315.605 5.868
202503 5.478 319.799 5.720
202506 4.341 322.561 4.494
202509 4.741 324.800 4.875
202512 5.034 324.054 5.188
202603 5.107 330.213 5.165
202606 4.845 333.952 4.845

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €21.09 mean?
Prestige Consumer Healthcare (FRA:PBV) has a Cyclically Adjusted Revenue per Share of €21.09 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Prestige Consumer Healthcare and its competitors.
Is Prestige Consumer Healthcare's Cyclically Adjusted Revenue per Share too high?
Prestige Consumer Healthcare's current Cyclically Adjusted Revenue per Share is €21.09. Overall, Prestige Consumer Healthcare has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Cyclically Adjusted Revenue per Share compare to BCRX and AMLX?
Prestige Consumer Healthcare's Cyclically Adjusted Revenue per Share of €21.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Prestige Consumer Healthcare and its competitors. Prestige Consumer Healthcare's current Cyclically Adjusted Revenue per Share is €21.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (FRA:PBV) is currently considered Modestly Undervalued. The stock's GF Value™ is €59.76, compared to a current price of €43.80 — trading 26.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €21.09. Prestige Consumer Healthcare's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Prestige Consumer Healthcare (FRA:PBV), the current Cyclically Adjusted Revenue per Share is €21.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?

Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued. The current stock price of €43.80 is trading 26.7% below its estimated GF Value™ of €59.76. GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.

Key valuation signals for FRA:PBV:

  • Cyclically Adjusted Revenue per Share: €21.09
  • GF Value™: €59.76 vs. price of €43.80 (26.7% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prestige Consumer Healthcare Business Description

Other Exchanges PBH:USA
Address 660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
72GF Score

Get the complete analysis for FRA:PBV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.80
Price
€59.76
GF Value